En vivo
CellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptationEndpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye diseaseEndpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease studyFierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugeLifeAltered cognitive processes shape tactile perception in autismeLifeCell size modulates ferroptosis susceptibilityClinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease RiskEndpoints NewsEli Lilly's claims data deadline may kick off new 340B fightClinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results
FierceBiotech 3 dic 2025

Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy

Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy

Original
Contenido no disponible. Consulta la fuente original.